Detail akcie Pulmonx Rg online

Business Summary: Pulmonx Corporation is a commercial-stage medical technology company. The Company provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Pulmonx Corp revenues increased 13% to $67.9M. Net loss increased 1% to $43.6M. Revenues reflect Europe, Middle-East and Africa ("EMEA") segment increase of 18% to $19.1M, Asia Pacific segment increase from $2.8M to $5.7M, United States segment increase of 6% to $42.9M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.11 to -$1.08.